Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly ...

Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.

The drug, sold under the brand name Kisunla and produced by drugmaker Eli Lilly, slows down the disease by up to 35%, ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Recent health developments include Eli Lilly's Alzheimer's treatment approval in China, a DOJ lawsuit against CVS for opioid ...

(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...